JP Morgan Maintains Overweight on Elevance Health, Raises Price Target to $411

Benzinga Newsdesk www.benzinga.com Positive 79.7%

Neg 0% Neu 0% Pos 79.7%

JP Morgan analyst Lisa Gill maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $397 to $411.